BACKGROUND: Ibrutinib therapy is associated with an increased risk of atrial fibrillation (AF) in chronic lymphocytic leukemia (CLL). Risk assessment tools and outcomes of AF in these patients are not well described. METHODS: We performed a retrospective review of patients with CLL treated with ibrutinib at Mayo Clinic between October 2012 and November 2018. RESULTS: Two hundred ninety-eight patients were identified with a median time on ibrutinib of 19 months (range 0.23-69.7 months). Fifty-one patients developed treatment-emergent AF; the risk of treatment-emergent AF at 6 months, 1 year, and 2 years was 9%, 12%, and 16%, respectively. The following were associated with an increased risk of treatment-emergent AF on multivariable analyses: past history of AF (hazard ratio [HR] 3.5, p = 0.0072) and heart failure (HR 3.4, p = 0.0028). Most patients are able to continue ibrutinib therapy (dose reduced in 43%). Development of treatment-emergent AF was associated with shorter event-free survival (EFS; HR 2.0, p = 0.02) and shorter overall survival (OS; HR 3.2, p = 0.001), after adjusting for age, prior treatment status, TP53 disruption, heart failure, valvular disease, and past history of AF. CONCLUSIONS: Patient comorbidities, rather than CLL-related factors, predict risk of treatment-emergent AF in patients treated with ibrutinib. Although the vast majority of patients with treatment-emergent AF are able to continue ibrutinib (with dose reduction in 43%), treatment-emergent AF appears to be associated with worse outcomes, independent of other adverse prognostic factors.
BACKGROUND: Ibrutinib therapy is associated with an increased risk of atrial fibrillation (AF) in chronic lymphocytic leukemia (CLL). Risk assessment tools and outcomes of AF in these patients are not well described. METHODS: We performed a retrospective review of patients with CLL treated with ibrutinib at Mayo Clinic between October 2012 and November 2018. RESULTS: Two hundred ninety-eight patients were identified with a median time on ibrutinib of 19 months (range 0.23-69.7 months). Fifty-one patients developed treatment-emergent AF; the risk of treatment-emergent AF at 6 months, 1 year, and 2 years was 9%, 12%, and 16%, respectively. The following were associated with an increased risk of treatment-emergent AF on multivariable analyses: past history of AF (hazard ratio [HR] 3.5, p = 0.0072) and heart failure (HR 3.4, p = 0.0028). Most patients are able to continue ibrutinib therapy (dose reduced in 43%). Development of treatment-emergent AF was associated with shorter event-free survival (EFS; HR 2.0, p = 0.02) and shorter overall survival (OS; HR 3.2, p = 0.001), after adjusting for age, prior treatment status, TP53 disruption, heart failure, valvular disease, and past history of AF. CONCLUSIONS: Patient comorbidities, rather than CLL-related factors, predict risk of treatment-emergent AF in patients treated with ibrutinib. Although the vast majority of patients with treatment-emergent AF are able to continue ibrutinib (with dose reduction in 43%), treatment-emergent AF appears to be associated with worse outcomes, independent of other adverse prognostic factors.
Entities:
Keywords:
Atrial fibrillation; Chronic lymphocytic leukemia; Ibrutinib; Small lymphocytic lymphoma
Authors: Tait D Shanafelt; Xin V Wang; Neil E Kay; Curtis A Hanson; Susan O'Brien; Jacqueline Barrientos; Diane F Jelinek; Esteban Braggio; Jose F Leis; Cong C Zhang; Steven E Coutre; Paul M Barr; Amanda F Cashen; Anthony R Mato; Avina K Singh; Michael P Mullane; Richard F Little; Harry Erba; Richard M Stone; Mark Litzow; Martin Tallman Journal: N Engl J Med Date: 2019-08-01 Impact factor: 91.245
Authors: Julie R McMullen; Esther J H Boey; Jenny Y Y Ooi; John F Seymour; Michael J Keating; Constantine S Tam Journal: Blood Date: 2014-12-11 Impact factor: 22.113
Authors: Selma Ugurel; Joachim Röhmel; Paolo A Ascierto; Keith T Flaherty; Jean Jacques Grob; Axel Hauschild; James Larkin; Georgina V Long; Paul Lorigan; Grant A McArthur; Antoni Ribas; Caroline Robert; Dirk Schadendorf; Claus Garbe Journal: Eur J Cancer Date: 2017-08-23 Impact factor: 9.162
Authors: Giuseppe Boriani; Paolo Corradini; Antonio Cuneo; Anna Falanga; Robin Foà; Gianluca Gaidano; Paolo Prospero Ghia; Maurizio Martelli; Roberto Marasca; Massimo Massaia; Francesca Romana Mauro; Giorgio Minotti; Stefano Molica; Marco Montillo; Antonio Pinto; Alessandra Tedeschi; Umberto Vitolo; Pier Luigi Zinzani Journal: Hematol Oncol Date: 2018-03-07 Impact factor: 5.271
Authors: Andrew H Lipsky; Mohammed Z H Farooqui; Xin Tian; Sabrina Martyr; Ann M Cullinane; Khanh Nghiem; Clare Sun; Janet Valdez; Carsten U Niemann; Sarah E M Herman; Nakhle Saba; Susan Soto; Gerald Marti; Gulbu Uzel; Steve M Holland; Jay N Lozier; Adrian Wiestner Journal: Haematologica Date: 2015-10-01 Impact factor: 9.941
Authors: Jan A Burger; Alessandra Tedeschi; Paul M Barr; Tadeusz Robak; Carolyn Owen; Paolo Ghia; Osnat Bairey; Peter Hillmen; Nancy L Bartlett; Jianyong Li; David Simpson; Sebastian Grosicki; Stephen Devereux; Helen McCarthy; Steven Coutre; Hang Quach; Gianluca Gaidano; Zvenyslava Maslyak; Don A Stevens; Ann Janssens; Fritz Offner; Jiří Mayer; Michael O'Dwyer; Andrzej Hellmann; Anna Schuh; Tanya Siddiqi; Aaron Polliack; Constantine S Tam; Deepali Suri; Mei Cheng; Fong Clow; Lori Styles; Danelle F James; Thomas J Kipps Journal: N Engl J Med Date: 2015-12-06 Impact factor: 91.245
Authors: John C Byrd; Jennifer R Brown; Susan O'Brien; Jacqueline C Barrientos; Neil E Kay; Nishitha M Reddy; Steven Coutre; Constantine S Tam; Stephen P Mulligan; Ulrich Jaeger; Steve Devereux; Paul M Barr; Richard R Furman; Thomas J Kipps; Florence Cymbalista; Christopher Pocock; Patrick Thornton; Federico Caligaris-Cappio; Tadeusz Robak; Julio Delgado; Stephen J Schuster; Marco Montillo; Anna Schuh; Sven de Vos; Devinder Gill; Adrian Bloor; Claire Dearden; Carol Moreno; Jeffrey J Jones; Alvina D Chu; Maria Fardis; Jesse McGreivy; Fong Clow; Danelle F James; Peter Hillmen Journal: N Engl J Med Date: 2014-05-31 Impact factor: 91.245
Authors: Jennifer R Brown; John C Byrd; Paolo Ghia; Jeff P Sharman; Peter Hillmen; Deborah M Stephens; Clare Sun; Wojciech Jurczak; John M Pagel; Alessandra Ferrajoli; Priti Patel; Lin Tao; Nataliya Kuptsova-Clarkson; Javid Moslehi; Richard R Furman Journal: Haematologica Date: 2022-06-01 Impact factor: 11.047